Nonlinearity and functional analysis: lectures on nonlinear problems in mathematical analysis

por Berger, Melvin S
Publicado 1977

Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency

por Berger, Melvin
Publicado 2008

Perspectives in nonlinearity: an introduction to nonlinear analysis

por Berger, Melvin S, Berger, Marion
Publicado 1968

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies: A Hypothesis Driven Approach

por Berger, Melvin, Allen, Jeffrey A
Publicado 2015

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens

por Chouksey, Akhilesh, Duff, Kimberly, Wasserbauer, Nancy, Berger, Melvin
Publicado 2005

Parthenolide inhibits ERK and AP-1 which are dysregulated and contribute to excessive IL-8 expression and secretion in cystic fibrosis cells

por Saadane, Aicha, Eastman, Jean, Berger, Melvin, Bonfield, Tracey L
Publicado 2011

Bioavailability of IgG Administered by the Subcutaneous Route

por Berger, Melvin, Jolles, Stephen, Orange, Jordan S., Sleasman, John W.
Publicado 2013

Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies

por Berger, Melvin, McCallus, Daniel E, Lin, Cindy Shin-Yi
Publicado 2013

Individualized immunoglobulin therapy in chronic immune‐mediated peripheral neuropathies*

por Allen, Jeffrey A., Berger, Melvin, Querol, Luis, Kuitwaard, Krista, Hadden, Robert D.
Publicado 2018

Hereditary angioedema C1-inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

por Farkas, Henriette, Fridman, Moshe, Supina, Dylan, Chiao, Joseph, Prusty, Subhransu, Berger, Melvin
Publicado 2019

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

por Farkas, Henriette, Levy, Donald, Supina, Dylan, Berger, Melvin, Prusty, Subhransu, Fridman, Moshe
Publicado 2020

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency

por Haddad, Elie, Berger, Melvin, Wang, Edward C. Y., Jones, Christopher A., Bexon, Martin, Baggish, Jeffrey S.
Publicado 2011

New Frontiers in Subcutaneous Immunoglobulin Treatment

por Jolles, Stephen, Stein, Mark R., Longhurst, Hilary J., Borte, Michael, Ritchie, Bruce, Sturzenegger, Matthias H., Berger, Melvin
Publicado 2011

Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability

por Dorsey, Morna J., Ho, Viet, Mabudian, Mohsen, Soler-Palacín, Pere, Domínguez-Pinilla, Nerea, Rishi, Radha, Rishi, Rahul, Wong, Duane, Rojavin, Mikhail, Hubsch, Alphonse, Berger, Melvin
Publicado 2014

Comprehensive Assessment of Serious Adverse Events Following Immunization by Health Care Providers

por Williams, S. Elizabeth, Edwards, Kathryn M., Baxter, Roger P., LaRussa, Philip S., Halsey, Neal A., Dekker, Cornelia L., Vellozzi, Claudia, Marchant, Colin D., Donofrio, Peter D., Reimschisel, Tyler E., Berger, Melvin, Gidudu, Jane F., Klein, Nicola P.
Publicado 2013